Aileron Therapeutics Acquires Lung Therapeutics

Linden Capital Partners Acquires Alcresta Therapeutics

March 12, 2024

Medical Devices

Chicago-based private equity firm Linden Capital Partners has completed its acquisition of Alcresta Therapeutics from a group led by Athyrium Capital, with Bessemer Venture Partners, Frazier Healthcare Partners and HealthQuest Capital also selling (HealthQuest reinvested as a minority shareholder). Linden will work with Alcresta's management and a newly assembled board to support the commercial launch of the next-generation RELiZORB device and accelerate R&D and growth.

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.

Blueprint Medicines Acquires Lengo Therapeutics

November 29, 2021

Biotechnology

Blueprint Medicines has entered a definitive agreement to acquire privately held precision oncology company Lengo Therapeutics for $250 million in cash plus up to $215 million in regulatory- and sales-based milestones. The deal adds Lengo’s lead oral EGFR exon 20 insertion candidate LNG-451 and other preclinical precision oncology programs to Blueprint’s lung cancer portfolio, expanding its capability in brain-penetrant EGFR inhibitors.

Altos Labs Acquires Dorian Therapeutics

May 23, 2025

Biotechnology

Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Johnson & Johnson MedTech Acquires Laminar, Inc.

November 30, 2023

Medical Devices

Johnson & Johnson MedTech has completed the acquisition of Laminar, Inc., a privately held medical device developer focused on eliminating the left atrial appendage (LAA) in patients with non‑valvular atrial fibrillation, for $400 million upfront plus potential clinical and regulatory milestone payments. Laminar will join Johnson & Johnson MedTech’s Biosense Webster business to expand the company’s electrophysiology and interventional cardiology portfolio and accelerate development and commercialization of Laminar’s rotational LAA elimination technology.